Background: To assess the dynamic changes in clinical and CT characteristics of COVID-19 patients with different epidemiology histories. Methods: Fifty-three discharged COVID-19 patients were enrolled at Beijing Youan Hospital, Capital Medical University, from Jan 21 to Mar 10, 2020. Spearman correlation analysis was performed between CT scores and laboratory indicators. Patients were divided into Wuhan (lived in/or traveled to Wuhan, 30 cases) and nonWuhan group (close contacts or unknown exposure, 23 cases). The CT and laboratory findings were compared between and within groups during the clinical process. Results: Fever (88.7%), cough (64.2%), fatigue (34%), and abnormal laboratory indicators, including lymphopenia, reduced albumin, albumin/globulin (A/G), and elevated C-reactive protein (CRP), were mainly observed. Subpleural ground-glass opacities (86.8%) were usually detected at admission. The CT scores were highly correlated with lymphocytes, CRP, albumin, and A/G at initial and follow-ups (all p<0.05). Four days after admission, most patients (66.7% Wuhan, 47.8% nonWuhan) showed progression, and the CT scores of Wuhan significantly increased (p=0.015). Eight days after admission, the vast majority of patients (69.2% Wuhan, 100% nonWuhan, p=0.006) presented improvement, and the CT scores of nonWuhan were significantly lower than Wuhan (p=0.006). Pneumonia was completely absorbed in most patients 2-4 weeks after discharge. Conclusions: CT plays a crucial role in early diagnosis and monitoring changes in COVID-19. Lymphocytes, CRP, albumin, and A/G are expected to predict disease severity and prognosis. Viral pathogenicity in non-endemic areas may be weaker than core-infected areas. Lung lesions can disappear around 4 weeks after discharge in most patients. Background In December 2019, there was an outbreak of novel viral pneumonia in Wuhan, China, which was proved to be associated with severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2) [1] and later named by World Health Organization (WHO) as the corona virus disease (COVID-19). COVID-19 initially affected mainly the person who worked or lived around the Huanan seafood market (Wuhan, China)[2, 3]. Then, the number of infected individuals soared and rapidly spread across all number BMU2018MX027]; Capital medical university research and incubation funding [grant number PYZ19162]; and Beijing Excellent Talent Plan [grant number 2018000021469G290]. The funders and sponsors had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. The researchers confirm their independence.
The findings of this prospective, observational study indicate that the recurrence risk is much higher after childbirth than during pregnancy in spite of higher utilization of psychotropic drugs in the postpartum period.
Postpartum depression is associated with adverse consequences for mother and offspring. The heritable ABO blood group has been associated with multiple diseases, including mental illness and diabetes. We explored the association of ABO blood group and postpartum depressive symptoms (PPDS) in a population-based cohort of pregnant Chinese women. From 2010 to August 2012, we recruited 8842 pregnant women with a mean age of 28.5 years (SD: 2.94) and mean body mass index of 22.4kg/m (SD: 3.45) in Tianjin, China. We used the Mainland Chinese version of the Edinburgh Postnatal Depression Scale after delivery with a cutoff score of 10 to define PPDS. Odds ratios (ORs) and 95% confidence intervals (CIs) for PPDS were obtained using binary logistic regression. Of 8842 women, 8.5% (n = 747) developed PPDS. Compared to those with blood group B, women with blood groups A, AB or O had a higher odds of PPDS (adjusted ORs: 1.23 (95% CI: 1.13-1.40), 1.31 (95% CI: 0.98-1.74), and 1.30(95% CI:1.03-1.60), respectively). Blood group B was associated with reduced odds of PPDS in pregnant Chinese women. If replicated in other studies, non-blood group B may be a useful risk factors for PPDS in Chinese pregnant women.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
customersupport@researchsolutions.com
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.